Greenyn Biotechnology (6846) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT
.7B, trading at NT$63.90 on the TWO. This SniperIQ fundamentals page covers Greenyn Biotechnology's valuation (P/E 13.1x, P/B 1.9x), profitability (net margin 15.0%), revenue (NT$915M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapNT
.7B
P/E (TTM)13.1x
Net Margin15.0%
Revenue (FY25)NT$915M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Greenyn Biotechnology's market cap?
Greenyn Biotechnology (6846) has a market capitalization of approximately NT
.7B, trading at NT$63.90 on the TWO. Market cap moves with the live share price.
What is Greenyn Biotechnology's P/E ratio?
Greenyn Biotechnology's trailing twelve-month P/E ratio is 13.1x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Greenyn Biotechnology?
Greenyn Biotechnology runs a net profit margin of 15.0%, a gross margin of 47.3%, and an operating margin of 19.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Greenyn Biotechnology generate?
Greenyn Biotechnology reported revenue of NT$915M for fiscal year 2025, with net income of NT
46M and earnings per share (EPS) of 5.39. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Greenyn Biotechnology pay a dividend?
Greenyn Biotechnology offers a trailing dividend yield of about 6.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Greenyn Biotechnology financially healthy?
Greenyn Biotechnology carries a debt-to-equity ratio of 1.10x and a current ratio of 3.85x, with a market beta of 0.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Greenyn Biotechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Greenyn Biotechnology (6846) the key facts are: market cap NT
.7B, P/E 13.1x, revenue NT$915M, 52-week range 62-78.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Greenyn Biotechnology's full fundamentals live
Get Greenyn Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.